98 Antibiotic prescription patterns for the treatment of Spanish cystic fibrosis patients: Results from a national multicentre survey study

Objectives To describe antibiotic (AB) prescription to Spanish cystic fibrosis (CF) patients over a 1-yr period, administration route and frequency of combined regimes. Oral azithromycin (AZT), dornase-alpha (Da) and inhaled hypertonic saline (IHS) use were recorded. Methods 24 CF Units (12 adult/12 pediatric) from 17 Spanish hospitals participated in a multicentre study (2013). Centres attend ∼75% of the Spanish CF population. Clinicians were asked to record prescribed treatments over a 1-yr period to the first 15 consecutive patients attending routinely to their units. Results 341 patients were included (12% of the Spanish CF population): Females 53%; mean age 21±11 yr; ≥18 yr 53%; mean %FEV 1 68±25; median exacerbations/yr 2 [0–12]; hospitalised patients 29%. 338 patients (99%) were receiving AB (Table) with 160 (47%) oral + inhaled, 10 (3%) oral + i.v., 4 (1%) inhaled+i.v. and 88 (26%) oral + inhaled + i.v. More than one inhaled antibiotic was administered to 67 patients (20%). Patients with inhaled colistin, tobramycin and aztreonam were 186 (68%), 90 (33%) and 22 (8%), respectively. Inhaled i.v. formulations were administered to 37 patients. AZT, IHS, Da and probiotics were used in 198 (58%), 204 (60%), 28 (8%) and 73 (23%) patients, respectively. TableNumber (%) of patients by type of therapyNumber (%) of patientsOral (N = 302, 89%)Inhaled (N = 273, 80%)i.v. (N = 105, 31%)Betalactams133 (44)44 (14)99 (94)Aminoglycosides−103 (38)68 (65)Quinolones207 (69)−7 (7)Colistin−186 (68)8 (8)Tetracyclines19 (6)−1 (1)Glycopeptides−9 (3)11 (11)Linezolid22 (7)−3 (3)Co-trimoxazole109 (36)−2 (2)Antifungals23 (8)1 (0.4)1 (1) Conclusion Antibiotic management of CF patients is challenging since the proportion of older patients with more advanced disease is high.